Fig. 3
Downregulation of MYPT1 increases tumorigenesis and resistance to platinum-based therapy in ovarian cancer cells in vivo and in vitro. a Quantification of the number of clones in the ES-2, SKOV3 or OVCAR8 ovarian cell lines expressing an EV (dark green), shMYPT1 or miR-30b (light green). b Growth curve of the ES-2, SKOV3 and OVCAR8 ovarian cell lines expressing an EV (dark green), shMYPT1 or miR-30b (light green) represented as doubling times. c Tumor growth in xenografts from SKOV3 and OVCAR8 cell lines expressing an EV (dark green) or shMYPT1 (light green), which were injected into female athymic nude mice (4 × 106 cells/ mouse). Cohorts of 5 mice each were used. d Determination of the IC50 (concentration of drug necessary to induce 50% cell death) for platinum drugs in cells overexpressing shMYPT1, miR-30b (light red) or EV (dark red). e Determination of the tumor volume and survival after cisplatin treatment in xenografts of SKOV3 cells expressing shMYPT1 or EV. Cohorts of 5 mice each were either treated with cisplatin or saline once the tumor reached 0.5 cm in diameter, and the survival rates were determined. All experiments were repeated at least three times. Data were analyzed using Student’s t-test. *, P < 0.05; **, P < 0.01; ***, P < 0.001